Abstract: Objective To study the clinical value of combined detection of 4 tumor markers, namely lactic dehydrogenate (LDH), tissue polypeptide specific antigen (TPS), carcinoembryonic antigen (CEA) and 32-microglobulin (β2-MG) in patients with non-Hodgkin’s lymphoma (NHL). Methods The serum level of LDH was determined with automatic biochemical analyzer and TPS, CEA and β2-MG levels were determined by enzyme-linked immumosorbent assay (ELISA) in 59 patients with NHL and 40 healthy adults. Results The levels of the 4 tumor markers were significantly higher in NHL patients than in the healthy control subjects (P<0.05). After chemotherapy, the serum levels of TPS and β2-MG were significantly lowered in the patients who showed favorable response to the treatment (P<0.05), but the levels of LDH and CEA showed no significant change (P>0.05). The serun levels of LDH, TPS, CEA and P2-MG in the patients in a stable or progressive phase did had no significant changes after chemotherapy (P>0.05). Conclusion Combined detection of LDH, TPS, CEA and β2-MG can be helpful to assist diagnosis of NHL and treatment evaluation.